A detailed history of Notis Mc Conarty Edward transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Notis Mc Conarty Edward holds 5,100 shares of GILD stock, worth $412,794. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,100
Previous 5,100 -0.0%
Holding current value
$412,794
Previous $373,000 6.43%
% of portfolio
0.14%
Previous 0.15%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

SELL
$62.32 - $89.47 $12,464 - $17,894
-200 Reduced 3.77%
5,100 $437,000
Q2 2022

Jul 19, 2022

SELL
$57.72 - $65.01 $161,616 - $182,028
-2,800 Reduced 34.57%
5,300 $328,000
Q3 2021

Nov 10, 2021

BUY
$67.69 - $73.03 $40,614 - $43,818
600 Added 8.0%
8,100 $566,000
Q2 2021

Aug 09, 2021

SELL
$63.47 - $69.35 $31,735 - $34,675
-500 Reduced 6.25%
7,500 $516,000
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $30,000 - $34,230
-500 Reduced 5.88%
8,000 $517,000
Q4 2020

Feb 16, 2021

SELL
$56.65 - $64.55 $141,625 - $161,375
-2,500 Reduced 22.73%
8,500 $495,000
Q1 2020

May 07, 2020

SELL
$62.63 - $80.22 $125 - $160
-2 Reduced 0.02%
11,000 $822,000
Q3 2019

Nov 04, 2019

SELL
$62.51 - $69.0 $625 - $690
-10 Reduced 0.09%
11,002 $698,000
Q1 2019

Apr 29, 2019

SELL
$62.53 - $70.05 $10,942 - $12,258
-175 Reduced 1.56%
11,012 $716,000
Q4 2018

Jan 24, 2019

SELL
$60.54 - $79.0 $1,816 - $2,370
-30 Reduced 0.27%
11,187 $700,000
Q3 2018

Oct 15, 2018

SELL
$71.28 - $78.92 $265,518 - $293,977
-3,725 Reduced 24.93%
11,217 $867,000
Q2 2018

Jul 30, 2018

SELL
$64.88 - $75.68 $21,410 - $24,974
-330 Reduced 2.16%
14,942 $1.06 Million
Q1 2018

Apr 24, 2018

BUY
$72.84 - $88.8 $5,463 - $6,660
75 Added 0.49%
15,272 $1.15 Million
Q3 2017

Oct 26, 2017

BUY
$72.11 - $85.47 $1.1 Million - $1.3 Million
15,197
15,197 $1.23 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $101B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Notis Mc Conarty Edward Portfolio

Follow Notis Mc Conarty Edward and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Notis Mc Conarty Edward, based on Form 13F filings with the SEC.

News

Stay updated on Notis Mc Conarty Edward with notifications on news.